Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Нефропротективные свойства сахароснижающих препаратов
Нефропротективные свойства сахароснижающих препаратов
Покровская Е.В., Трубицына Н.П., Зайцева Н.В. Нефропротективные свойства сахароснижающих препаратов. Consilium Medicum. 2019; 21 (4): 35–39. DOI: 10.26442/20751753.2019.4.190332
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Диабетическая нефропатия – одно из микрососудистых осложнений сахарного диабета, которое является основной причиной развития терминальной стадии хронической болезни почек, требующей проведения заместительной почечной терапии (диализ, трансплантация почки). Качество и продолжительность жизни пациентов на диализе очень низкие, а лечение требует большого количества материальных затрат, поэтому важное значение уделяется предупреждению развития и прогрессирования диабетической нефропатии. Первичная профилактика включает в себя поддержание целевого уровня гликемии и гликированного гемоглобина, артериального давления, липидного спектра, для вторичной профилактики помимо перечисленных показателей используются препараты из группы блокаторов ренин-ангиотензин-альдостероновой системы. Также в течение последних лет появилось несколько классов новых сахароснижающих препаратов (ингибиторы натрий-глюкозного котранспортера 2-го типа – иНГЛТ-2, агонисты глюкагоноподобного пептида 1-го типа, ингибиторы дипептидилпептидазы 4-го типа), влияющих не только на уровень гликемии и метаболические показатели, но и на функцию почек. В данном обзоре проанализированы результаты крупных международных рандомизированных исследований с оценкой нефропротективных свойств сахароснижающих препаратов из групп иНГЛТ-2, агонистов глюкагоноподобного пептида 1-го типа и ингибиторов дипептидилпептидазы 4-го типа. В исследованиях препаратов группы иНГЛТ-2 можно говорить о класс-эффекте по снижению сердечно-сосудистых и почечных рисков и рекомендовать их применение при доказанных сердечно-сосудистых заболеваниях и хронической болезни почек. Говоря о группе препаратов инкретинового ряда, можно сделать вывод об их сердечно-сосудистой безопасности, а в некоторых исследованиях и положительном влиянии на функцию почек в виде снижения альбуминурии. Исходя из полученных данных возникает большой интерес к изучению прямого нефропротективного действия данных препаратов, который может иметь принципиальную роль в профилактике развития и прогрессирования диабетической нефропатии.
Ключевые слова: сахарный диабет 2-го типа, диабетическая нефропатия, нефропротекция, ингибиторы натрий-глюкозного котранспортера 2-го типа, инкретины, агонисты глюкагоноподобного пептида 1-го типа, ингибиторы дипептидилпептидазы 4-го типа.
Ключевые слова: сахарный диабет 2-го типа, диабетическая нефропатия, нефропротекция, ингибиторы натрий-глюкозного котранспортера 2-го типа, инкретины, агонисты глюкагоноподобного пептида 1-го типа, ингибиторы дипептидилпептидазы 4-го типа.
________________________________________________
Diabetic nephropathy is one of microvascular complications of diabetes mellitus, which is the leading cause of end-stage renal disease, requiring renal replacement therapy (dialysis, kidney transplantation). The quality and life expectancy of patients on dialysis is very low, and treatment requires significant material costs, therefore, a high priority is accorded to the prevention of the development and the progression of diabetic nephropathy. Primary prophylaxis is aimed at maintaining the target level of glycemia and glycated hemoglobin, blood pressure, lipid spectrum, for the secondary prevention, in addition to the above-mentioned indicators, drugs from RAAS blockers group are used. Also, in recent years, several classes of new glucose-lowering drugs (iSGLT-2, aGLP-1, iDPP-4) have appeared, affecting not only glycemia and metabolic parameters, but also renal function.
In this review, we analyzed the results of large-scale international randomized trials designed to assess the nephroprotective properties of glucose-lowering drugs from the iSGLT-2, aGLP-1 and iDPP-4 groups. In studies with iSGLT-2 group, it is possible to speak of a class effect on the reduction of cardiovascular and renal risks and recommend their use for proven CVD and CKD. In the group of incretin drugs, one may infer, that they are cardiovascular safe, and in some studies, a positive effect on renal function in the form of reduced AU has been shown. Based on the data obtained, there is great interest in the study of the direct nephroprotective effect of these drugs, which may have a fundamental role in preventing the development and the progression of diabetic nephropathy.
Key words: diabetes mellitus type 2, diabetic nephropathy, nephroprotection, incretins, SGLT-2 inhibitors, GLP-1 agonists, DPP-4 inhibitors.
In this review, we analyzed the results of large-scale international randomized trials designed to assess the nephroprotective properties of glucose-lowering drugs from the iSGLT-2, aGLP-1 and iDPP-4 groups. In studies with iSGLT-2 group, it is possible to speak of a class effect on the reduction of cardiovascular and renal risks and recommend their use for proven CVD and CKD. In the group of incretin drugs, one may infer, that they are cardiovascular safe, and in some studies, a positive effect on renal function in the form of reduced AU has been shown. Based on the data obtained, there is great interest in the study of the direct nephroprotective effect of these drugs, which may have a fundamental role in preventing the development and the progression of diabetic nephropathy.
Key words: diabetes mellitus type 2, diabetic nephropathy, nephroprotection, incretins, SGLT-2 inhibitors, GLP-1 agonists, DPP-4 inhibitors.
Полный текст
Список литературы
1. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический отчет по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017; 20 (1): 13–41. DOI: 10.14341/DM8664
[Dedov I.I., Shestakova M.V., Vikulova O.K. Epidemiologiia sakharnogo diabeta v Rossiiskoi Federatsii: kliniko-statisticheskii otchet po dannym Federal'nogo registra sakharnogo diabeta. Sakharnyi diabet. 2017; 20 (1): 13–41. DOI: 10.14341/DM8664 (in Russian).]
2. Cho NH, Shaw JE, Karuranga S et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045/2018; 138: 271–81. DOI: 10.1016/j.diabres.2018.02.023
3. Fioretto P, Zambon A, Rossato M et al. SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care 2016; 39 (2): 165–71. DOI: 10.2337/dcS15-3006
4. Modafferi S, Ries M, Calabrese V et al. Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis. Diabetes Ther 2019; 10 (1): 229–43.
5. Шамхалова М.Ш., Викулова О.К., Железнякова А.В. и др. Эпидемиология хронической болезни почек в Российской Федерации по данным Федерального регистра взрослых пациентов с сахарным диабетом (2013–2016 гг.). Сахарный диабет. 2018; 21 (3): 160–9. DOI: 10.14341/DM9687
[Shamkhalova M.Sh., Vikulova O.K., Zhelezniakova A.V. et al. Epidemiologiia khronicheskoi bolezni pochek v Rossiiskoi Federatsii po dannym Federal'nogo registra vzroslykh patsientov s sakharnym diabetom (2013–2016 gg.). Sakharnyi diabet. 2018; 21 (3): 160–9. DOI: 10.14341/DM9687 (in Russian).]
6. Prischl FC, Wanner C. Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition. Kidney Int Rep 2018; 3 (5): 1030–8. DOI: 10.1016/j.ekir.2018.04.008
7. Górriz JL, Nieto J, Navarro-González JF et al. Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? J Clin Med 2015; 4 (10): 1866–89. DOI: 10.3390/jcm4101866
8. Levin A, Stevens PE, Bilous RW et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter (Suppl.) 2013; 3 (1): 1–150. DOI: 10.1038/kisup.2012.73
9. Шестакова М.В., Шамхалова М.Ш., Ярек-Мартынова И.Я. и др. Клинические рекомендации по диагностике, скринингу, профилактике и лечению хронической болезни почек у больных сахарным диабетом. 2014. https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/pohki.pdf
[Shestakova M.V., Shamkhalova M.Sh., Iarek-Martynova I.Ia. et al. Klinicheskie rekomendatsii po diagnostike, skriningu, profilaktike i lecheniiu khronicheskoi bolezni pochek u bol'nykh sakharnym diabetom. 2014. https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/pohki.pdf (in Russian).]
10. Penno G, Garofolo M, Del Prato S. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutrit, Metab Cardiovasc Dis 2016; 26 (5): 361–73. DOI: 10.1016/j.numecd.2016.01.001
11. Байрашева В.К., Бабенко А.Ю., Байрамов А.А. и др. Перспективы нефропротекции при сахарном диабете 2-го типа с использованием ингибитора ДПП-4 вилдаглиптина. Мед. совет. 2017; 3: 8–16. DOI: 10.21518/2079-701X-2017-3-8-16
[Bairasheva V.K., Babenko A.Iu., Bairamov A.A. et al. Perspektivy nefroprotektsii pri sakharnom diabete 2-go tipa s ispol'zovaniem ingibitora DPP-4 vildagliptina. Med. sovet. 2017; 3: 8–16. DOI: 10.21518/2079-701X-2017-3-8-16 (in Russian).]
12. Davies MJ, D'Alessio DA, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61 (12): 2461–98. DOI: 10.1007/s00125-018-4729-5
13. Moses RG, Colagiuri S, Pollock C. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. Australas Med J 2014; 7 (10): 405–15. DOI: 10.4066/AMJ.2014.2181
14. Шестакова М.В., Сухарева О.Ю. Глифлозины: особенности сахароснижающего действия и негликемические эффекты нового класса препаратов. Клин. фармакология и терапия. 2016; 25 (2): 65–71.
[Shestakova M.V., Sukhareva O.Iu. Glifloziny: osobennosti sakharosnizhaiushchego deistviia i neglikemicheskie effekty novogo klassa preparatov. Klin. farmakologiia i terapiia. 2016; 25 (2): 65–71 (in Russian).]
15. Dekkers CCJ, Gansevoort RT, Heerspink HJL. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Curr Diab Rep 2018; 18 (5): 27. DOI: 10.1007/s11892-018-0992-6
16. Корбут А.И., Климонтов В.В. Эмпаглифлозин: новая стратегия нефропротекции при сахарном диабете. Сахарный диабет. 2017; 20 (1): 75–84. DOI: 10.14341/DM8005
[Korbut A.I., Klimontov V.V. Empagliflozin: novaia strategiia nefroprotektsii pri sakharnom diabete. Sakharnyi diabet. 2017; 20 (1): 75–84. DOI: 10.14341/DM8005 (in Russian).]
17. Heerspink Hiddo JL, Kosiborod М, Inzucchi Silvio E et al. Kidney International. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018; 94 (1): 26–39. DOI: 10.1016/j.kint.2017.12.027
18. Yehya A, Sadhu AR. New Therapeutic Strategies for Type 2 Diabetes. Methodist Debakey Cardiovasc J 2018; 14 (4): 281–8. DOI: 10.14797/mdcj-14-4-281
19. Alicic RZ, Johnson EJ, and Tuttle KR. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. J Kidney Dis 2017; 72 (2): 267–77. DOI: 10.1053/j.ajkd.2018.03.022
20. Mahaffey KW, Neal B, Perkovic V et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018; 137 (4): 323–34. DOI: 10.1161/CIRCULATIONAHA.117.032038
21. Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review – safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes 2019; 12: 209–15. DOI: 10.2147/DMSO.S184437
22. Herrington WG, Preiss D, Haynes R et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J 2018; 11 (6): 749–61. DOI: 10.1093/ckj/sfy090
23. Jardine MJ, Mahaffey KW, Neal B et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol 2017; 46 (6): 462–72. DOI: 10.1159/000484633
24. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380 (4): 347–57. DOI: 10.1056/NEJMoa1812389
25. Zelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31–9. DOI: 10.1016/S0140-6736 (18)32590-X
26. Standl E, Schnell O, McGuire DK et al. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabet Endocrinol 2017; 5 (5): 391–402. DOI: 10.1016/s2213-8587 (17)30033-5
27. Lim S, Kim KM, Nauck MA. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. Trends Endocrinol Metab 2018; 29 (4): 238–48. DOI: 10.1016/j.tem.2018.01.011
28. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311–22. DOI: 10.1056/NEJMoa1603827
29. Prischl FC, Wanner C. Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition. Kidney Int Rep 2018; 3 (5): 1030–8. DOI: 10.1016/j.ekir.2018.04.008
30. Dey AK, Groenendyk J, Mehta NN, Gourgari E. The Effect of SGLT-2 inhibitors and GLP-1 Agonists on Cardiovascular Disease in Patients with Type 2 Diabetes. Clin Cardiol 2019; 42 (3): 406–12. DOI: 10.1002/clc.23152
31. Hernandez AF, Green JB, Janmohamed S et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392 (10157): 1519–29. DOI: 10.1016/s0140-6736 (18)32261-x
32. Fioretto P, Frascati A. Role of incretin based therapies in the treatment of diabetic kidney disease. Diabetes Mellitus 2018; 21 (5): 395–8. DOI: 10.14341/DM9845
33. Schnell O, Standl E, Catrinoiu D et al. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol 2016; 15: 33. DOI: 10.1186/s12933-016-0357-x
2. Cho NH, Shaw JE, Karuranga S et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045/2018; 138: 271–81. DOI: 10.1016/j.diabres.2018.02.023
3. Fioretto P, Zambon A, Rossato M et al. SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care 2016; 39 (2): 165–71. DOI: 10.2337/dcS15-3006
4. Modafferi S, Ries M, Calabrese V et al. Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis. Diabetes Ther 2019; 10 (1): 229–43.
5. Shamkhalova M.Sh., Vikulova O.K., Zhelezniakova A.V. et al. Epidemiologiia khronicheskoi bolezni pochek v Rossiiskoi Federatsii po dannym Federal'nogo registra vzroslykh patsientov s sakharnym diabetom (2013–2016 gg.). Sakharnyi diabet. 2018; 21 (3): 160–9. DOI: 10.14341/DM9687 (in Russian).
6. Prischl FC, Wanner C. Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition. Kidney Int Rep 2018; 3 (5): 1030–8. DOI: 10.1016/j.ekir.2018.04.008
7. Górriz JL, Nieto J, Navarro-González JF et al. Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? J Clin Med 2015; 4 (10): 1866–89. DOI: 10.3390/jcm4101866
8. Levin A, Stevens PE, Bilous RW et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter (Suppl.) 2013; 3 (1): 1–150. DOI: 10.1038/kisup.2012.73
9. Shestakova M.V., Shamkhalova M.Sh., Iarek-Martynova I.Ia. et al. Klinicheskie rekomendatsii po diagnostike, skriningu, profilaktike i lecheniiu khronicheskoi bolezni pochek u bol'nykh sakharnym diabetom. 2014. https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/pohki.pdf (in Russian).
10. Penno G, Garofolo M, Del Prato S. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutrit, Metab Cardiovasc Dis 2016; 26 (5): 361–73. DOI: 10.1016/j.numecd.2016.01.001
11. Bairasheva V.K., Babenko A.Iu., Bairamov A.A. et al. Perspektivy nefroprotektsii pri sakharnom diabete 2-go tipa s ispol'zovaniem ingibitora DPP-4 vildagliptina. Med. sovet. 2017; 3: 8–16. DOI: 10.21518/2079-701X-2017-3-8-16 (in Russian).
12. Davies MJ, D'Alessio DA, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61 (12): 2461–98. DOI: 10.1007/s00125-018-4729-5
13. Moses RG, Colagiuri S, Pollock C. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. Australas Med J 2014; 7 (10): 405–15. DOI: 10.4066/AMJ.2014.2181
14. Shestakova M.V., Sukhareva O.Iu. Glifloziny: osobennosti sakharosnizhaiushchego deistviia i neglikemicheskie effekty novogo klassa preparatov. Klin. farmakologiia i terapiia. 2016; 25 (2): 65–71 (in Russian).
15. Dekkers CCJ, Gansevoort RT, Heerspink HJL. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Curr Diab Rep 2018; 18 (5): 27. DOI: 10.1007/s11892-018-0992-6
16. Korbut A.I., Klimontov V.V. Empagliflozin: novaia strategiia nefroprotektsii pri sakharnom diabete. Sakharnyi diabet. 2017; 20 (1): 75–84. DOI: 10.14341/DM8005 (in Russian).
17. Heerspink Hiddo JL, Kosiborod М, Inzucchi Silvio E et al. Kidney International. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018; 94 (1): 26–39. DOI: 10.1016/j.kint.2017.12.027
18. Yehya A, Sadhu AR. New Therapeutic Strategies for Type 2 Diabetes. Methodist Debakey Cardiovasc J 2018; 14 (4): 281–8. DOI: 10.14797/mdcj-14-4-281
19. Alicic RZ, Johnson EJ, and Tuttle KR. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. J Kidney Dis 2017; 72 (2): 267–77. DOI: 10.1053/j.ajkd.2018.03.022
20. Mahaffey KW, Neal B, Perkovic V et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018; 137 (4): 323–34. DOI: 10.1161/CIRCULATIONAHA.117.032038
21. Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review – safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes 2019; 12: 209–15. DOI: 10.2147/DMSO.S184437
22. Herrington WG, Preiss D, Haynes R et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J 2018; 11 (6): 749–61. DOI: 10.1093/ckj/sfy090
23. Jardine MJ, Mahaffey KW, Neal B et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol 2017; 46 (6): 462–72. DOI: 10.1159/000484633
24. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380 (4): 347–57. DOI: 10.1056/NEJMoa1812389
25. Zelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31–9. DOI: 10.1016/S0140-6736 (18)32590-X
26. Standl E, Schnell O, McGuire DK et al. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabet Endocrinol 2017; 5 (5): 391–402. DOI: 10.1016/s2213-8587 (17)30033-5
27. Lim S, Kim KM, Nauck MA. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. Trends Endocrinol Metab 2018; 29 (4): 238–48. DOI: 10.1016/j.tem.2018.01.011
28. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311–22. DOI: 10.1056/NEJMoa1603827
29. Prischl FC, Wanner C. Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition. Kidney Int Rep 2018; 3 (5): 1030–8. DOI: 10.1016/j.ekir.2018.04.008
30. Dey AK, Groenendyk J, Mehta NN, Gourgari E. The Effect of SGLT-2 inhibitors and GLP-1 Agonists on Cardiovascular Disease in Patients with Type 2 Diabetes. Clin Cardiol 2019; 42 (3): 406–12. DOI: 10.1002/clc.23152
31. Hernandez AF, Green JB, Janmohamed S et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392 (10157): 1519–29. DOI: 10.1016/s0140-6736 (18)32261-x
32. Fioretto P, Frascati A. Role of incretin based therapies in the treatment of diabetic kidney disease. Diabetes Mellitus 2018; 21 (5): 395–8. DOI: 10.14341/DM9845
33. Schnell O, Standl E, Catrinoiu D et al. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol 2016; 15: 33. DOI: 10.1186/s12933-016-0357-x
[Dedov I.I., Shestakova M.V., Vikulova O.K. Epidemiologiia sakharnogo diabeta v Rossiiskoi Federatsii: kliniko-statisticheskii otchet po dannym Federal'nogo registra sakharnogo diabeta. Sakharnyi diabet. 2017; 20 (1): 13–41. DOI: 10.14341/DM8664 (in Russian).]
2. Cho NH, Shaw JE, Karuranga S et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045/2018; 138: 271–81. DOI: 10.1016/j.diabres.2018.02.023
3. Fioretto P, Zambon A, Rossato M et al. SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care 2016; 39 (2): 165–71. DOI: 10.2337/dcS15-3006
4. Modafferi S, Ries M, Calabrese V et al. Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis. Diabetes Ther 2019; 10 (1): 229–43.
5. Шамхалова М.Ш., Викулова О.К., Железнякова А.В. и др. Эпидемиология хронической болезни почек в Российской Федерации по данным Федерального регистра взрослых пациентов с сахарным диабетом (2013–2016 гг.). Сахарный диабет. 2018; 21 (3): 160–9. DOI: 10.14341/DM9687
[Shamkhalova M.Sh., Vikulova O.K., Zhelezniakova A.V. et al. Epidemiologiia khronicheskoi bolezni pochek v Rossiiskoi Federatsii po dannym Federal'nogo registra vzroslykh patsientov s sakharnym diabetom (2013–2016 gg.). Sakharnyi diabet. 2018; 21 (3): 160–9. DOI: 10.14341/DM9687 (in Russian).]
6. Prischl FC, Wanner C. Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition. Kidney Int Rep 2018; 3 (5): 1030–8. DOI: 10.1016/j.ekir.2018.04.008
7. Górriz JL, Nieto J, Navarro-González JF et al. Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? J Clin Med 2015; 4 (10): 1866–89. DOI: 10.3390/jcm4101866
8. Levin A, Stevens PE, Bilous RW et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter (Suppl.) 2013; 3 (1): 1–150. DOI: 10.1038/kisup.2012.73
9. Шестакова М.В., Шамхалова М.Ш., Ярек-Мартынова И.Я. и др. Клинические рекомендации по диагностике, скринингу, профилактике и лечению хронической болезни почек у больных сахарным диабетом. 2014. https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/pohki.pdf
[Shestakova M.V., Shamkhalova M.Sh., Iarek-Martynova I.Ia. et al. Klinicheskie rekomendatsii po diagnostike, skriningu, profilaktike i lecheniiu khronicheskoi bolezni pochek u bol'nykh sakharnym diabetom. 2014. https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/pohki.pdf (in Russian).]
10. Penno G, Garofolo M, Del Prato S. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutrit, Metab Cardiovasc Dis 2016; 26 (5): 361–73. DOI: 10.1016/j.numecd.2016.01.001
11. Байрашева В.К., Бабенко А.Ю., Байрамов А.А. и др. Перспективы нефропротекции при сахарном диабете 2-го типа с использованием ингибитора ДПП-4 вилдаглиптина. Мед. совет. 2017; 3: 8–16. DOI: 10.21518/2079-701X-2017-3-8-16
[Bairasheva V.K., Babenko A.Iu., Bairamov A.A. et al. Perspektivy nefroprotektsii pri sakharnom diabete 2-go tipa s ispol'zovaniem ingibitora DPP-4 vildagliptina. Med. sovet. 2017; 3: 8–16. DOI: 10.21518/2079-701X-2017-3-8-16 (in Russian).]
12. Davies MJ, D'Alessio DA, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61 (12): 2461–98. DOI: 10.1007/s00125-018-4729-5
13. Moses RG, Colagiuri S, Pollock C. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. Australas Med J 2014; 7 (10): 405–15. DOI: 10.4066/AMJ.2014.2181
14. Шестакова М.В., Сухарева О.Ю. Глифлозины: особенности сахароснижающего действия и негликемические эффекты нового класса препаратов. Клин. фармакология и терапия. 2016; 25 (2): 65–71.
[Shestakova M.V., Sukhareva O.Iu. Glifloziny: osobennosti sakharosnizhaiushchego deistviia i neglikemicheskie effekty novogo klassa preparatov. Klin. farmakologiia i terapiia. 2016; 25 (2): 65–71 (in Russian).]
15. Dekkers CCJ, Gansevoort RT, Heerspink HJL. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Curr Diab Rep 2018; 18 (5): 27. DOI: 10.1007/s11892-018-0992-6
16. Корбут А.И., Климонтов В.В. Эмпаглифлозин: новая стратегия нефропротекции при сахарном диабете. Сахарный диабет. 2017; 20 (1): 75–84. DOI: 10.14341/DM8005
[Korbut A.I., Klimontov V.V. Empagliflozin: novaia strategiia nefroprotektsii pri sakharnom diabete. Sakharnyi diabet. 2017; 20 (1): 75–84. DOI: 10.14341/DM8005 (in Russian).]
17. Heerspink Hiddo JL, Kosiborod М, Inzucchi Silvio E et al. Kidney International. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018; 94 (1): 26–39. DOI: 10.1016/j.kint.2017.12.027
18. Yehya A, Sadhu AR. New Therapeutic Strategies for Type 2 Diabetes. Methodist Debakey Cardiovasc J 2018; 14 (4): 281–8. DOI: 10.14797/mdcj-14-4-281
19. Alicic RZ, Johnson EJ, and Tuttle KR. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. J Kidney Dis 2017; 72 (2): 267–77. DOI: 10.1053/j.ajkd.2018.03.022
20. Mahaffey KW, Neal B, Perkovic V et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018; 137 (4): 323–34. DOI: 10.1161/CIRCULATIONAHA.117.032038
21. Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review – safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes 2019; 12: 209–15. DOI: 10.2147/DMSO.S184437
22. Herrington WG, Preiss D, Haynes R et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J 2018; 11 (6): 749–61. DOI: 10.1093/ckj/sfy090
23. Jardine MJ, Mahaffey KW, Neal B et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol 2017; 46 (6): 462–72. DOI: 10.1159/000484633
24. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380 (4): 347–57. DOI: 10.1056/NEJMoa1812389
25. Zelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31–9. DOI: 10.1016/S0140-6736 (18)32590-X
26. Standl E, Schnell O, McGuire DK et al. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabet Endocrinol 2017; 5 (5): 391–402. DOI: 10.1016/s2213-8587 (17)30033-5
27. Lim S, Kim KM, Nauck MA. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. Trends Endocrinol Metab 2018; 29 (4): 238–48. DOI: 10.1016/j.tem.2018.01.011
28. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311–22. DOI: 10.1056/NEJMoa1603827
29. Prischl FC, Wanner C. Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition. Kidney Int Rep 2018; 3 (5): 1030–8. DOI: 10.1016/j.ekir.2018.04.008
30. Dey AK, Groenendyk J, Mehta NN, Gourgari E. The Effect of SGLT-2 inhibitors and GLP-1 Agonists on Cardiovascular Disease in Patients with Type 2 Diabetes. Clin Cardiol 2019; 42 (3): 406–12. DOI: 10.1002/clc.23152
31. Hernandez AF, Green JB, Janmohamed S et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392 (10157): 1519–29. DOI: 10.1016/s0140-6736 (18)32261-x
32. Fioretto P, Frascati A. Role of incretin based therapies in the treatment of diabetic kidney disease. Diabetes Mellitus 2018; 21 (5): 395–8. DOI: 10.14341/DM9845
33. Schnell O, Standl E, Catrinoiu D et al. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol 2016; 15: 33. DOI: 10.1186/s12933-016-0357-x
________________________________________________
2. Cho NH, Shaw JE, Karuranga S et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045/2018; 138: 271–81. DOI: 10.1016/j.diabres.2018.02.023
3. Fioretto P, Zambon A, Rossato M et al. SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care 2016; 39 (2): 165–71. DOI: 10.2337/dcS15-3006
4. Modafferi S, Ries M, Calabrese V et al. Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis. Diabetes Ther 2019; 10 (1): 229–43.
5. Shamkhalova M.Sh., Vikulova O.K., Zhelezniakova A.V. et al. Epidemiologiia khronicheskoi bolezni pochek v Rossiiskoi Federatsii po dannym Federal'nogo registra vzroslykh patsientov s sakharnym diabetom (2013–2016 gg.). Sakharnyi diabet. 2018; 21 (3): 160–9. DOI: 10.14341/DM9687 (in Russian).
6. Prischl FC, Wanner C. Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition. Kidney Int Rep 2018; 3 (5): 1030–8. DOI: 10.1016/j.ekir.2018.04.008
7. Górriz JL, Nieto J, Navarro-González JF et al. Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? J Clin Med 2015; 4 (10): 1866–89. DOI: 10.3390/jcm4101866
8. Levin A, Stevens PE, Bilous RW et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter (Suppl.) 2013; 3 (1): 1–150. DOI: 10.1038/kisup.2012.73
9. Shestakova M.V., Shamkhalova M.Sh., Iarek-Martynova I.Ia. et al. Klinicheskie rekomendatsii po diagnostike, skriningu, profilaktike i lecheniiu khronicheskoi bolezni pochek u bol'nykh sakharnym diabetom. 2014. https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/pohki.pdf (in Russian).
10. Penno G, Garofolo M, Del Prato S. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutrit, Metab Cardiovasc Dis 2016; 26 (5): 361–73. DOI: 10.1016/j.numecd.2016.01.001
11. Bairasheva V.K., Babenko A.Iu., Bairamov A.A. et al. Perspektivy nefroprotektsii pri sakharnom diabete 2-go tipa s ispol'zovaniem ingibitora DPP-4 vildagliptina. Med. sovet. 2017; 3: 8–16. DOI: 10.21518/2079-701X-2017-3-8-16 (in Russian).
12. Davies MJ, D'Alessio DA, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61 (12): 2461–98. DOI: 10.1007/s00125-018-4729-5
13. Moses RG, Colagiuri S, Pollock C. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. Australas Med J 2014; 7 (10): 405–15. DOI: 10.4066/AMJ.2014.2181
14. Shestakova M.V., Sukhareva O.Iu. Glifloziny: osobennosti sakharosnizhaiushchego deistviia i neglikemicheskie effekty novogo klassa preparatov. Klin. farmakologiia i terapiia. 2016; 25 (2): 65–71 (in Russian).
15. Dekkers CCJ, Gansevoort RT, Heerspink HJL. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Curr Diab Rep 2018; 18 (5): 27. DOI: 10.1007/s11892-018-0992-6
16. Korbut A.I., Klimontov V.V. Empagliflozin: novaia strategiia nefroprotektsii pri sakharnom diabete. Sakharnyi diabet. 2017; 20 (1): 75–84. DOI: 10.14341/DM8005 (in Russian).
17. Heerspink Hiddo JL, Kosiborod М, Inzucchi Silvio E et al. Kidney International. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018; 94 (1): 26–39. DOI: 10.1016/j.kint.2017.12.027
18. Yehya A, Sadhu AR. New Therapeutic Strategies for Type 2 Diabetes. Methodist Debakey Cardiovasc J 2018; 14 (4): 281–8. DOI: 10.14797/mdcj-14-4-281
19. Alicic RZ, Johnson EJ, and Tuttle KR. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. J Kidney Dis 2017; 72 (2): 267–77. DOI: 10.1053/j.ajkd.2018.03.022
20. Mahaffey KW, Neal B, Perkovic V et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018; 137 (4): 323–34. DOI: 10.1161/CIRCULATIONAHA.117.032038
21. Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review – safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes 2019; 12: 209–15. DOI: 10.2147/DMSO.S184437
22. Herrington WG, Preiss D, Haynes R et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J 2018; 11 (6): 749–61. DOI: 10.1093/ckj/sfy090
23. Jardine MJ, Mahaffey KW, Neal B et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol 2017; 46 (6): 462–72. DOI: 10.1159/000484633
24. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380 (4): 347–57. DOI: 10.1056/NEJMoa1812389
25. Zelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31–9. DOI: 10.1016/S0140-6736 (18)32590-X
26. Standl E, Schnell O, McGuire DK et al. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabet Endocrinol 2017; 5 (5): 391–402. DOI: 10.1016/s2213-8587 (17)30033-5
27. Lim S, Kim KM, Nauck MA. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. Trends Endocrinol Metab 2018; 29 (4): 238–48. DOI: 10.1016/j.tem.2018.01.011
28. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311–22. DOI: 10.1056/NEJMoa1603827
29. Prischl FC, Wanner C. Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition. Kidney Int Rep 2018; 3 (5): 1030–8. DOI: 10.1016/j.ekir.2018.04.008
30. Dey AK, Groenendyk J, Mehta NN, Gourgari E. The Effect of SGLT-2 inhibitors and GLP-1 Agonists on Cardiovascular Disease in Patients with Type 2 Diabetes. Clin Cardiol 2019; 42 (3): 406–12. DOI: 10.1002/clc.23152
31. Hernandez AF, Green JB, Janmohamed S et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392 (10157): 1519–29. DOI: 10.1016/s0140-6736 (18)32261-x
32. Fioretto P, Frascati A. Role of incretin based therapies in the treatment of diabetic kidney disease. Diabetes Mellitus 2018; 21 (5): 395–8. DOI: 10.14341/DM9845
33. Schnell O, Standl E, Catrinoiu D et al. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol 2016; 15: 33. DOI: 10.1186/s12933-016-0357-x
Авторы
Е.В.Покровская*, Н.П.Трубицына, Н.В.Зайцева
ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия
*pokrovskaya.93@mail.ru
ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия
*pokrovskaya.93@mail.ru
________________________________________________
Elena V. Pokrovskaya*, Natalia P. Trubitsyna, Natalia V. Zaytseva
Endocrinology Research Centre, Moscow, Russia
*pokrovskaya.93@mail.ru
Endocrinology Research Centre, Moscow, Russia
*pokrovskaya.93@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.